The Evolution of EGFR-mutated Advanced NSCLC Treatment: A Brief Review

home / around-the-practice / the-evolution-of-egfr-mutated-advanced-nsclc-treatment-a-brief-review

Samuel Rosner, MD, discusses how the treatment landscape for EGFR-mutated non-small cell lung cancer has evolved from first-generation targeted therapies to osimertinib as the current standard of care, while exploring emerging options like fourth-generation TKIs, antibody-drug conjugates, and bispecific therapies to overcome resistance mechanisms.

1 expert is featured in this series.

EP. 1: The Evolution of EGFR-Mutated Advanced NSCLC Treatment: Present Considerations and Future Treatment Options

Samuel Rosner, MD
June 27th 2025

Samuel Rosner, MD, discusses how the treatment landscape for EGFR-mutated non–small cell lung cancer has evolved from first-generation targeted therapies to osimertinib as the current standard of care, while exploring emerging options like fourth-generation tyrosine kinase inhibitors, antibody-drug conjugates, and bispecific therapies to overcome resistance mechanisms.